MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

MiMedx Group is back in focus as analysts revisit their price targets, with several firms trimming expectations by roughly US$1 to US$5 while the modeled fair value sits at US$6.50. Those moves line up with research that balances optimism about MiMedx Group's business against concerns around execution and how the stock is currently priced. Read on to see what these shifts could mean for you and how to track the evolving analyst narrative from here.

Stay updated as the Fair Value for MiMedx Group shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on MiMedx Group.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Across Craig Hallum, Lake Street, Citizens and Northland, MiMedx Group is still covered with explicit price targets. This signals that analysts see enough visibility in the business to keep publishing detailed valuation work.

• The latest target revisions cluster around a modeled fair value of about US$6.50. This suggests that, even after trims, analysts continue to see potential upside versus where many investors may currently be anchoring expectations.

🐻 Bearish Takeaways

• Craig Hallum, Lake Street, Citizens and Northland have each cut their price targets on MiMedx Group by roughly US$1 to US$5. This reflects a more cautious stance on how the story is playing out.

• The repeated target reductions through April 2026 highlight ongoing worries about execution and how confidently MiMedx Group can deliver against prior assumptions around growth and profitability.

• With several firms lowering targets in quick succession, analysts are signaling greater sensitivity to valuation. This implies that investors may need stronger proof points before assigning higher multiples to the stock.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 2 risks for MiMedx Group. See which could impact your investment.

How This Changes the Fair Value For MiMedx Group

• Fair value stays at US$6.50, with no change from the prior estimate.

• Revenue growth is still modeled as a decline of 3.55%, matching the earlier assumption.

• Net profit margin remains at 2.46%, with only a very small technical adjustment.

• The future P/E multiple is effectively unchanged at 140.41x.

• The discount rate moves slightly lower from 7.1639% to 7.1632%.